<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04499001</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A01380-39</org_study_id>
    <nct_id>NCT04499001</nct_id>
  </id_info>
  <brief_title>Effect of Pharmaceutical Consultations Just Before Rheumatology Consultations on Improving Knowledge and Skills for Patients With Inflammatory Arthritis With Subcutaneous Biologic DMARDs</brief_title>
  <official_title>Effect of Pharmaceutical Consultations Just Before Rheumatology Consultations on Improving Knowledge and Skills for Patients With Inflammatory Arthritis Treated With Subcutaneous Biologic DMARDs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hôpital Cochin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hôpital Cochin</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is a lack of knowledge among patients concerning their treatment with bDMARDs. To&#xD;
      increase knowledge and safety skills, patient education is essential.&#xD;
&#xD;
      The aim of this study is to assess the impact of a pharmacist's educational interview on on&#xD;
      knowledge and safety skills to bDMARDs in patients with inflammatory arthritis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational, controlled, open-label and monocentric study. 60 patients are&#xD;
      planned to be included.&#xD;
&#xD;
      Knowledge are assessed three time by self-administered questionnaire:&#xD;
&#xD;
      at baseline before the pharmacist's educational interview at three months apart at six months&#xD;
      apart&#xD;
&#xD;
      One primary end-point is defined:&#xD;
&#xD;
      the changes from baseline to M3 and M6 in the patients' knowledge score about subcutaneous&#xD;
      bDMARD management (self-administered questionnaire, Biosecure)&#xD;
&#xD;
      As secondary end-points, the changes from baseline to M3 and M6 in patients' adherence,&#xD;
      patients' satisfaction regarding the pharmacists' intervention and the effect of the&#xD;
      interview on rate of patients treated by biosimilar are evaluated.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in bDMARDS knowledge and skills at 3 and 6 months in patients who received a pharmaceutical consultation</measure>
    <time_frame>6 months of follow-up</time_frame>
    <description>Knowledge level and score comparison (good or moderate or bad knowledge) evaluated by self-questionnaire (Biosecure) from baseline to M3 and M6 after the pharmaceutical consultation.&#xD;
Biosecure : Minimum = 0 ; Maximum = 100 Good knowledge &gt; 84 Moderate knoledge : 64 to 84 Bad knowledge &lt; 64&#xD;
Higher scores mean a better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in bDMARDS adherence at 3 and 6 months in patients who received a pharmaceutical consultation</measure>
    <time_frame>6 months of follow-up</time_frame>
    <description>Adherence level comparison (high or low adherence) evaluated by self-questionnaire, Compliance Questionnaire for Rheumatology (CQR-5) from baseline to M3 and M6 after the consultation.&#xD;
High adherence means a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction of patients on the pharmaceutical interview 3 months apart</measure>
    <time_frame>3 months of follow-up</time_frame>
    <description>Assessment of patients' satisfaction on the pharmaceutical interview at 3 months of the consultation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in rate of patients treated by biosimilar after the pharmaceutical consultation</measure>
    <time_frame>6 months of follow-up</time_frame>
    <description>Comparison of patient treated by biosimilar rate from baseline to M3 and M6 after the consultation</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Arthritis, Rheumatoid</condition>
  <condition>Spondyloarthritis</condition>
  <condition>Biological Therapy</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacist's consultation</intervention_name>
    <description>Information about bDMARDs management.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with subcutaneous bDMARDs with inflammatory arthritis admitted in medical&#xD;
        consultation in the rheumatology department&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be able to understand and communicate in French and comply with the&#xD;
             requirements of the study and must give his agreement (non-opposition) before any&#xD;
             study assessment is performed.&#xD;
&#xD;
          -  Patient at least 18 years of age&#xD;
&#xD;
          -  Patient with inflammatory arthritis (rheumatoid arthritis or ankylosing spondylitis or&#xD;
             other)&#xD;
&#xD;
          -  Admission in medical consultation in the rheumatology department&#xD;
&#xD;
          -  Patient treated with subcutaneous biologic DMARDs (Tocilizumab, Adalimumab,&#xD;
             Etanercept, Golimumab, Certolizumab, Abatacept, Sarilumab, Ustekinumab, Ixekizumab,&#xD;
             Anakinra)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medical or psychiatric condition which, in the Investigator's opinion, would&#xD;
             preclude the participant from completing the study per protocol&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Cécile Bottois, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Cochin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cécile Bottois, Dr</last_name>
    <phone>+33 1 58 41 23 02</phone>
    <email>cecile.bottois@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ornella Conort, Dr</last_name>
    <phone>+ 33 1 58 41 23 07</phone>
    <email>ornella.conort@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cécile Bottois, Dr</last_name>
      <phone>+33 1 58 41 23 02</phone>
      <email>cecile.bottois@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Ornella Conort, Dr</last_name>
      <phone>+33 1 58 41 23 07</phone>
      <email>ornella.conort@aphp.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Cécile Bottois, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ornella Conort, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Maxime Dougados, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 22, 2020</study_first_submitted>
  <study_first_submitted_qc>July 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 5, 2020</study_first_posted>
  <last_update_submitted>July 30, 2020</last_update_submitted>
  <last_update_submitted_qc>July 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hôpital Cochin</investigator_affiliation>
    <investigator_full_name>Cécile Bottois</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>knowledge</keyword>
  <keyword>safety skills</keyword>
  <keyword>pharmaceutical consultation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

